Abstract
Lung disease is a major morbidity of rheumatoid arthritis (RA). Lung involvement is heterogeneous, and may occur in some form in over 50% of patients with RA. Clinically apparent interstitial lung disease (ILD) affects about 8 % of patients, most commonly usual interstitial pneumonitis. Pulmonary disease is a major cause of death in patients with RA; patients with ILD have a median survival of 2.6 years following diagnosis of the lung disease, lowest in patients with diffuse alveolar damage. Risk factors for RA related lung disease include male sex, older age, smoking, and more severe RA with erosive joint and other extraarticular involvement. Drugs used in management of RA may be associated with pulmonary toxicity, including methotrexate, leflunomide and some biologics. In ILD, lung function studies show a restrictive pattern, with low DLC0 a sensitive parameter of early ILD. High resolution chest computed tomography is sensitive for demonstrating ILD. Treatment of RA associated lung disease is guided by the type of pulmonary disease, recognizing that control of the underlying RA is critical to reducing the impact of disease related comorbidities. Much remains to be done to better understand the pathogenesis and management of this disease manifestation.
Keywords: Interstitial lung disease, lung disease, rheumatoid arthritis.
Current Respiratory Medicine Reviews
Title:The Lung Disease of Rheumatoid Arthritis
Volume: 11 Issue: 2
Author(s): Megan L. Krause, Ana C. Zamora, Robert Vassallo, Jay H. Ryu and Eric L. Matteson
Affiliation:
Keywords: Interstitial lung disease, lung disease, rheumatoid arthritis.
Abstract: Lung disease is a major morbidity of rheumatoid arthritis (RA). Lung involvement is heterogeneous, and may occur in some form in over 50% of patients with RA. Clinically apparent interstitial lung disease (ILD) affects about 8 % of patients, most commonly usual interstitial pneumonitis. Pulmonary disease is a major cause of death in patients with RA; patients with ILD have a median survival of 2.6 years following diagnosis of the lung disease, lowest in patients with diffuse alveolar damage. Risk factors for RA related lung disease include male sex, older age, smoking, and more severe RA with erosive joint and other extraarticular involvement. Drugs used in management of RA may be associated with pulmonary toxicity, including methotrexate, leflunomide and some biologics. In ILD, lung function studies show a restrictive pattern, with low DLC0 a sensitive parameter of early ILD. High resolution chest computed tomography is sensitive for demonstrating ILD. Treatment of RA associated lung disease is guided by the type of pulmonary disease, recognizing that control of the underlying RA is critical to reducing the impact of disease related comorbidities. Much remains to be done to better understand the pathogenesis and management of this disease manifestation.
Export Options
About this article
Cite this article as:
Krause L. Megan, Zamora C. Ana, Vassallo Robert, Ryu H. Jay and Matteson L. Eric, The Lung Disease of Rheumatoid Arthritis, Current Respiratory Medicine Reviews 2015; 11 (2) . https://dx.doi.org/10.2174/1573398X11666150619184024
DOI https://dx.doi.org/10.2174/1573398X11666150619184024 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recombinant Human Regenerating Gene 4 Attenuates the Severity of
Osteoarthritis by Promoting the Proliferation of Articular Chondrocyte
in an Animal Model
Current Molecular Pharmacology Covid-19: Pathophysiology; Mechanism of Transmission and Possible Molecular Drug Target for Management
Current Molecular Pharmacology The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery Novel Concepts for Anti-Infective Activity of Cytokines, Chemokines and Diverse Agents
Recent Patents on Anti-Infective Drug Discovery Sphingolipids in Inflammation: Roles and Implications
Current Molecular Medicine An Overview of Nano Delivery Systems for Targeting RNA Interference-based Therapy in Ulcerative Colitis
Current Pharmaceutical Design Metabolism of HDL and its Regulation
Current Medicinal Chemistry Tetracyclines: Drugs with Huge Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Formulation and Evaluation of Liposomal Drug Delivery System for Sulfasalazine
Current Nanomedicine Dehydroepiandrosterone (DHEA): A Steroid with Multiple Effects. Is there Any Possible Option in the Treatment of Critical illness?
Current Medicinal Chemistry Activation of Central Pain Pathways in Rheumatic Diseases: What We have Learned from Functional Neuroimaging Studies
Current Rheumatology Reviews Adenoviral Vector-Mediated Gene Transfer for Human Gene Therapy
Current Gene Therapy Molecular Mechanisms of Glucocorticoids Action: From Basic Research to Clinical Implications
Current Immunology Reviews (Discontinued) Defining Novel Targets for Intervention in Rheumatoid Arthritis: An Overview
Current Rheumatology Reviews Epigenetic Modulation: A Promising Avenue to Advance Hematopoietic Stem Cell-Based Therapy for Severe Autoimmune Disorders
Epigenetic Diagnosis & Therapy (Discontinued) Anti-TNFs for Postoperative Recurrence in Crohns Disease: The Ifs and Hows
Current Drug Targets The Therapeutic Potential of Adenosine Triphosphate as an Immune Modulator in the Treatment of HIV/AIDS: A Combination Approach with HAART
Current HIV Research Inflammatory Pathways in Knee Osteoarthritis: Potential Targets for Treatment
Current Rheumatology Reviews Resources and Tools for Investigating Biomolecular Networks in Mammals
Current Pharmaceutical Design The Discovery of VLA-4 Antagonists
Current Topics in Medicinal Chemistry